glp-1 agonist and dpp-4 inhibitor Role of Inhibitors in Clinical Practice DPP4 Inhibitors vs GLP-1 Agonists
Description
This is not failure
Patients in large clinical trials for GLP-1s lost an average of 15% to 20% of their body weight, depending on the drug they were given
Zanotto, C
Oral alternatives like orforglipron (when available) or Qsymia eliminate storage concerns entirely
The A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults with Obesity (SURMOUNT-MMO) trial assesses tirzepatide's impact on mortality and cardiovascular events in overweight or obese individuals
Sullivan, C
